Core Laboratories (CLB)

Oilfield services company Core Laboratories (NYSE:CLB) announced better-than-expected revenue in Q4 CY2025, with sales up 7% year on year to $138.3 million. Its non-GAAP profit of $0.21 per share was 10.5% above analysts’ consensus estimates.

Company Overview

With roots dating back to the first commercial oil boom, Core Laboratories (NYSE:CLB) analyzes rock and fluid samples from oil and gas reservoirs to help energy companies optimize production and recovery.

Oilfield services companies provide equipment, technology, and services enabling exploration and production activities, including drilling, completion, well intervention, and reservoir evaluation. Their fortunes closely track upstream capital spending cycles. Tailwinds include increased drilling activity during favorable commodity environments, demand for efficiency-enhancing technologies, and growing offshore and unconventional resource development. Headwinds include significant revenue volatility tied to oil and gas price swings and producer spending discipline. Intense competition pressures pricing and margins, while the energy transition may structurally reduce long-term demand. Workforce availability and technological disruption require continuous adaptation.

Core Laboratories competes with diversified oilfield service providers like Schlumberger (NYSE:SLB) and Halliburton (NYSE:HAL), as well as specialized reservoir analysis firms like Weatherford International (NASDAQ:WFRD) and private laboratory service companies.

The size of the revenue base is a way to assess topline, and it tells an investor whether an Energy producer has crossed the line between being a more vulnerable commodity taker and a durable operating platform. Scaled businesses tend to produce and generate revenue from many wells, pads, takeaway routes, and geographies, not just a single field or drilling program. Core Laboratories’s $526.5 million of revenue in the last year is pretty small for the industry, suggesting the company hasn’t hit a level of diversification where investors can sleep easy at night.

A company’s long-term performance can give signals about its business quality. Even a bad business, especially in a cyclical industry, can shine for a year or so, but a top-tier one should exhibit resilience through cycles. Unfortunately, Core Laboratories’s 1.6% annualized revenue growth over the last five years was weak. This was below our standards and is a poor baseline for our analysis.

Within Energy, a singular timeframe, even if it’s quite long-term, only sheds light on how well a company rode the last commodity cycle. To better assess whether a company compounds through cycles, we validate our view with an even longer, ten-year view. Core Laboratories’s performance shows it grew in the past five-year but relinquished its gains over the last ten years, as its revenue fell by 4.1% annually.

This quarter, Core Laboratories reported year-on-year revenue growth of 7%, and its $138.3 million of revenue exceeded Wall Street’s estimates by 3.5%.

While energy gross margins can be distorted by commodity prices, hedging, and short-term cost swings, sustained margins across a full cycle reflect a producer’s underlying asset quality, infrastructure position, and cost structure.

Core Laboratories, which averaged 20.7% gross margin over the last five years, exhibiting bottom-tier unit economics in the sector. It means the company will struggle at higher commodity prices than peers with better gross margins.

This quarter, Core Laboratories’s gross profit margin was 20.8%, up 3 percentage points year on year.

Core Laboratories was profitable over the last five years but held back by its large cost base. Its average EBITDA margin of 14.4% was among the worst in the energy upstream and integrated energy sector.

Looking at the trend in its profitability, Core Laboratories’s EBITDA margin decreased by 1.1 percentage points over the last year. Core Laboratories’s performance was poor no matter how you look at it - it shows that costs were rising and it couldn’t pass them onto its customers.

In Q4, Core Laboratories generated an EBITDA margin profit margin of 14%, in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable. This adjusted EBITDA beat Wall Street’s estimates by 1.5%.

Adjusted EBITDA shows how profitable a company’s existing wells are before financing and reinvestment decisions, but free cash flow shows how much value remains after paying the cost of replacing those wells. In upstream energy, production naturally declines over time, so companies must continuously reinvest just to stand still. A producer can report strong EBITDA margins yet generate little or no free cash flow if its wells decline quickly or if new drilling is expensive. Free cash flow therefore captures not only how efficiently a company produces hydrocarbons today, but also how costly it is to sustain that production into the future.

Core Laboratories has shown weak cash profitability relative to peers over the last five years, giving the company fewer opportunities to return capital to shareholders. Its free cash flow margin averaged 4.7%, below what we’d expect for an upstream and integrated energy business.

While the level of free cash flow margins is important, their consistency matters just as much.

Core Laboratories’s ratio of quarterly free cash flow volatility to WTI crude price volatility over the past five years was 6.4 (lower is better), indicating excellent insulation from commodity swings. This stability supports capital access in downturns and positions Core Laboratories to act as a consolidator when weaker peers are forced to retrench.

You may be asking why we wait until the free cash flow line to perform this stability analysis versus commodity prices. Why not compare revenue or EBITDA to WTI in the case of Core Laboratories? Because what ultimately matters is not how much revenue or profit you earn when prices are high but how much cash you can generate when prices are low. Free cash flow is the superior metric because it includes everything from hedging prowess to growth and maintenance capex to management behavior during good times and bad.

Core Laboratories’s free cash flow clocked in at $4.44 million in Q4, equivalent to a 3.2% margin. The company’s cash profitability regressed as it was 9.4 percentage points lower than in the same quarter last year, prompting us to pay closer attention. Short-term fluctuations typically aren’t a big deal because investment needs can be seasonal, but we’ll be watching to see if the trend extrapolates into future quarters.

Free cash flow shows how much money a producer generated, while ROIC shows how efficiently that money was earned. ROIC measures the operating profit produced for each dollar of capital invested, whether from debt or equity. Cash generation measures quantity while ROIC measures the quality of value creation.

We at StockStory like to look at ROIC over a ten-year period because energy investment cycles can involve up to five years of ramping production and another five years of harvesting. A decade view captures buying, extracting, and monetizing rather than just part of that picture. Although Core Laboratories hasn’t been the highest-quality company lately because of its poor top-line performance, it historically found a few growth initiatives that worked out well. Its ten-year average ROIC was 16.1%, impressive for an upstream and integrated energy business.

We like to invest in businesses with high returns, but the trend in a company’s ROIC is what often surprises the market and moves the stock price. Fortunately, Core Laboratories’s ROIC averaged 1.1 percentage point increases each year over the last few years. This is a good sign, and we hope the company can keep improving.

Core Laboratories reported $22.85 million of cash and $121.7 million of debt on its balance sheet in the most recent quarter. As investors in high-quality companies, we primarily focus on two things: 1) that a company’s debt level isn’t too high and 2) that its interest payments are not excessively burdening the business.

With $73.38 million of EBITDA over the last 12 months, we view Core Laboratories’s 1.3× net-debt-to-EBITDA ratio as safe. We also see its $10.57 million of annual interest expenses as appropriate. The company’s profits give it plenty of breathing room, allowing it to continue investing in growth initiatives.

We enjoyed seeing Core Laboratories beat analysts’ revenue expectations this quarter. We were also glad its EPS outperformed Wall Street’s estimates. Overall, we think this was a decent quarter with some key metrics above expectations. The stock remained flat at $16.31 immediately following the results.

Updated: March 24, 2026 at 1:13 AM EDT

Before making an investment decision, investors should account for Core Laboratories’s business fundamentals and valuation in addition to what happened in the latest quarter.

Core Laboratories falls short of our quality standards. To begin with, its revenue growth over the last five years was bottom-tier for the sector, and analysts don’t see anything changing over the next 12 months. While its market-beating ROIC suggests it has been a well-managed company historically, the downside is its EBITDA margins reveal bottom-tier profitability compared to other energy upstream and integrated energy companies. On top of that, its gross margins show its business model is much less lucrative than other companies.

Core Laboratories’s P/E ratio based on the next 12 months is 22.1x. This multiple tells us a lot of good news is priced in - we think there are better stocks to buy right now.

Wall Street analysts have a consensus one-year price target of $15.83 on the company (compared to the current share price of $16.10).